Colorectal cancer incidence is increasing among young adults
the ONA take:
Screening efforts have resulted in an overall decrease in incidence of colorectal cancer (CRC). However, incidence of the disease in young adults (ages 20-39 years) has increased in the past 20 to 30 years.
Little is known about CRC incidence in young adults because recommended screening for people of average risk person begins at age 50 years. Researchers at the University of California, Irvine, analyzed 231,544 CRC cases from 1988-2009 from the California Cancer Registry to identify high-risk subgroups.
Their study cases included 5,617 young adults ages 20-39 years. Although the absolute incidence of CRC per 100,000 in this group was low, the researchers found CRC incidence increasing over time among both males and females, particularly for distal colon cancer in Hispanic females ages 20-29 years.
The researchers conclude that absolute incidence of CRC is significantly lower in among the young adult populations; however, incidence is increasing among young adults compared with the older screened population. They also note a need for further research to better characterize young adults at increased risk for CRC.
Incidence of colorectal cancer in young adults has increased in the past 20 to 30 years.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|